Study of AGEN1571 in Participants With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1571 as a Single Agent and in Combination With a PD-1 Inhibitor and/or Botensilimab (AGEN1181) in Patients With Advanced Solid Tumors
Sponsor: Agenus Inc.
A PHASE1 clinical study on Advanced Solid Tumor, this trial is completed. The trial is conducted by Agenus Inc. and has accumulated 9 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Apr 2023 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .